Lancet Neurology

Article	Citations
Multidisciplinary care for amyotrophic lateral sclerosis	1048
Correction to Lancet Neurol 2021; 20: 448–59	899
Correction to Lancet Neurol 2024; 23: 168–77	849
Continuous subcutaneous levodopa–carbidopa infusion for Parkinson's disease	726
RAB32 mutation in Parkinson's disease	673
Traumatic brain injury research: homogenising heterogeneity	580
The predictive value and clinical use of the neurological pupillary index – Authors' reply	525
Treatment-induced neuropathy of diabetes: an underdiagnosed entity – Authors' reply	480
Increasing diversity in dementia research	475
Lessons and future directions for GBA1-targeting therapies	454
Correction to Lancet Neurol 2022; 21: 42–52	445
New therapies for Pompe disease: are we closer to a cure?	413
Dementia diagnosis in the anti-amyloid era	375
Implications of the KIWE trial for low-income and lower-middle-income countries	369
Correction to Lancet Neurol 2020; 19: 391–401	346
Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study	341
Global burden of stroke: dynamic estimates to inform action	337
Correction to Lancet Neurol 2025; 24: 850–65	298
Clinical descriptors of disease trajectories in patients with traumatic brain injury in the intensive care unit (CENTER-TBI): a multicentre observational cohort study	284
Safety and efficacy of early versus delayed acetylsalicylic acid after surgery for spontaneous intracerebral haemorrhage in China (E-start): a prospective, multicentre, open-label, blinded-endpoint, r	265
The East Asian Parkinson Disease Genomics Consortium	241
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study	239
A biological classification of Huntington's disease: the Integrated Staging System	236
Bailout intracranial angioplasty or stenting following thrombectomy for acute large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label, blinded-endpoint, randomised controlled trial	235
Management of atherosclerotic extracranial carotid artery stenosis	234

Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study	221
Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study	206
The relevance of social and commercial determinants for neurological health	201
Anti-CD19 CAR T cells for refractory myasthenia gravis	190
Surrogate endpoints for progressive multifocal leukoencephalopathy	185
The prescription of valproate: risk of harm	184
Diana Cejas	181
The Genetic Epidemiology of Parkinson's Disease view – Authors' reply	181
Considering the neurological health needs of LGBTQIA people	180
Beyond the modular brain	177
Elia M Pestana Knight	177
Aspiring to restore arm and hand function after stroke	161
Albert Kwaku Akpalu	160
A sensitive portrayal of a controversial condition	158
A chilly tale of dementia	156
A nasal CGRP receptor antagonist for acute migraine therapy	155
A study in healing the wounds of trauma	153
Trials in intracerebral haemorrhage: a path to success?	151
Correction to Lancet Neurol 2023; 22: 812–25	150
Delving into the human mind	149
Correction to Lancet Neurol 2022; 21: 284–94	146
Epilepsy syndromes: an essential piece of the puzzle	144
Development of treatments for Down syndrome	134
Movement disorders research in 2021: cracking the paradigm	134
Gene therapy for X-linked myotubular myopathy: the challenges	133
Parkinson's disease is a recognisable and useful diagnostic entity	132
From stroke awareness to stroke action awareness	122
Amyotrophic lateral sclerosis from genotoxins alone?	120
Neuropathology of Alzheimer's disease after anti-amyloid β antibody treatment	119
Global burden of headache disorders: innovations, disparities, and priorities for action	118
Safe laboratory management of prions and proteopathic seeds	118
Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trial	117
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised contro	117
Complex regional pain syndrome: advances in epidemiology, pathophysiology, diagnosis, and treatment	115
Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm tri	114
Intracranial pressure monitoring with and without brain tissue oxygen pressure monitoring for severe traumatic brain injury in France (OXY-TC): an open-label, randomised controlled superiority trial	113
B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases	112
Functional or hysterical?	110
Cognitive function in people with functional seizures	109
Rethinking AI trials in brain health	108
A proposal for equity neuroscience	108
Changing multiple-sclerosis-induced thoughts and behaviours	103
Supporting young carers across neurological disorders	102
Learning to be an adult with a disability	101
The ATTeST trial in ataxia telangiectasia: some concerns – Authors' response	101
Multiple sclerosis in 2022: old players, new insights	100
Revisiting candesartan: new evidence for an old option in migraine prevention	100
A health literacy campaign for Parkinson's disease in Africa: a novel campaign to break down language barriers	97
Riluzole and spinocerebellar ataxia type 2: the ATRIL trial	95
New results for risdiplam in spinal muscular atrophy	94

Expansion of stenting indications in the USA	94
Responsible innovation in neurology	91
Better buildings for elderly people to thrive	90
Correction to Lancet Neurol 2024; 23: 110–22	90
The International Brain Initiative: enabling collaborative science	89
Correction to Lancet Neurol 2022; 21: 620–31	88
Jessica Ailani	88
Brain health in the Philippines	87
Encephalitis awareness: our ambitious global endeavour	86
Neurological infections in 2023: surveillance and prevention	85
Major advances in Parkinson's disease over the past two decades and future research directions	84
Detection of ionising radiation by the CNS: a case report	84
Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial	83
α-synuclein seed amplification and its uses in Parkinson's disease	83
Spontaneous intracranial hypotension: searching for the CSF leak	81
Effect of blood pressure-lowering agents on microvascular function in people with small vessel diseases (TREAT-SVDs): a multicentre, open-label, randomised, crossover trial	81
Safety and efficacy of intra-erythrocyte dexamethasone sodium phosphate in children with ataxia telangiectasia (ATTeST): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial	80
A new characterisation of acute traumatic brain injury: the NIH-NINDS TBI Classification and Nomenclature Initiative	78
Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study	78
Improving thrombolysis efficiency for acute ischaemic stroke	78
Detection of awareness after brain injury: time for change	78
ELEVATEd hope for patients after migraine treatment failure	76
Pragmatic solutions for the global burden of stroke	76
Highlights in traumatic brain injury research in 2024	75
A call for optimal oral care in patients with ALS	75
Correction to Lancet Neurol 2024; 23: 961–62	70
Neuroprotection in acute ischaemic stroke: reasons for optimism?	69
Monitoring brainwaves while gallery visitors view artworks	69
Expanding the spectrum of type 1 IFN neuroinflammation	69
Andrea Schneider	69
Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phas	68
The global challenge of hypertension	68
Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial	65
Consciousness contextualised	64
Thrombolysis before endovascular treatment of tandem lesions	64
Siddharth Srivastava	63
Targeting auto-antibodies for CIDP: hope and questions	63
Correction to Lancet Neurol 2024; 23: 344–81	62
Safety and efficacy of tamoxifen in boys with Duchenne muscular dystrophy (TAMDMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	60
The AfrAbia+plus Parkinson's Disease Genomic Consortium	60
Epilepsy research in 2022: clinical advances	59
Eugenia Martínez	58
Blocking inhibitors of axon growth after spinal cord injury	57
Living with dementia: seeing the world and adapting to it	55
Your After-Visit Summary—May 29, 2042	54
Headache research in 2023: advancing therapy and technology	54
Bastiaan Bloem: power against Parkinson's disease	54
Sleeping matters	54
Effect of atherosclerosis on 5-year risk of major vascular events in patients with transient ischaemic attack or minor ischaemic stroke: an international prospective cohort study	53
Brains are neither pink nor blue but fifty shades of grey matter	53
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind,	52
Neurorehabilitation as a cornerstone of recovery	52
Caution on the use of α2δ-ligands in neuropathic pain	52
Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges	51
Diagnosis and treatment of orthostatic hypotension	51
Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial	51
Whole genome sequencing for the diagnosis of neurological repeat expansion disorders in the UK: a retrospective diagnostic accuracy and prospective clinical validation study	51
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation	51
Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations	50
Angela Dos Santos	49
The torment of needing to know for sure	49
Correction to Lancet Neurol 2024; 23: 465–76	49
Therapies for myasthenia gravis: FcRn inhibition and beyond	49
Challenging the management of blood pressure before intravenous thrombolysis in acute ischaemic stroke	48
Changing the landscape of neurological education	48
NfL is ready for translation into paediatrics	47
Essential medicines for neurological disorders: updates, rejections, and the road ahead	47
The four most common genetic subtypes of amyotrophic lateral sclerosis: state of the art and future directions	47
Charles Bell's Renaissance inspiration	47
Over a decade of MR-guided focused ultrasound	46
No area of stroke research should be left behind	46
Tenecteplase versus alteplase in stroke thrombolysis: the last piece of the puzzle?	46
The bases of remembrance	45
Geoffrey Manley: TBI guy	44
Major advances in sleep neurology: 2002–22	44
Early atrial fibrillation rhythm control after stroke	44
The cultural history of dementia	43
Carlayne Jackson: leading the American Academy of Neurology	43
Neurosurgical lesioning for Tourette syndrome – Authors' reply	43
Further support for rituximab in relapsing multiple sclerosis	42

Platelet glycoprotein VI inhibition: a promising therapeutic avenue in acute ischaemic stroke	42
A brain design for life	42
Charles Sherrington's apparatus	41
Sleep research in 2023: beyond the bare necessities	41
Digital mobility measures to predict Parkinson's disease	41
Laquinimod, Huntington's disease, and disease modification	40
For a dementia diagnosis, clinical acumen must precede biomarkers	40
Biomedical research must change as the climate does	40
A decisive year for the neurological community	39
Correction to Lancet Neurol 2021; 20: 1012–16	39
Thank you to The Lancet Neurology's peer reviewers in 2023	39
Frailty and outcome after traumatic brain injury	38
Tenecteplase versus alteplase for early treatment of ischaemic stroke – Authors' reply	38
Differential diagnosis and comparison of diagnostic algorithms in children and adolescents with autoimmune encephalitis in Spain: a prospective cohort study and retrospective analysis	37
Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders	36
Diagnostic and other biomarkers of dementia with Lewy bodies: from research to clinical settings	36
Improving epilepsy diagnosis across the lifespan: approaches and innovations	35
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial	35
Advances in amyotrophic lateral sclerosis research in 2022	34
Stimulation of TREM2 with agonistic antibodies—an emerging therapeutic option for Alzheimer's disease	34
The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI–neuropathology diagnostic accuracy study	33
Safety and efficacy of trehalose in amyotrophic lateral sclerosis (HEALEY ALS Platform Trial): an adaptive, phase 2/3, double-blind, randomised, placebo-controlled trial	32
The complex pathway between amyloid β and cognition: implications for therapy	32
Nanna Brix Finnerup: integrity and openness to alternatives	31
Video games for people with neurological disorders	31
Acute-onset axonal neuropathy following infection in children with biallelic RCC1 variants: a case series	31
The prescription of valproate: risk of harm	30
Neuroscience in the 21st century: circuits, computation, and behaviour	30
Correction to Lancet Neurol 2024; 23: 344–81	30
Maria Trojano: advocate for real-world multiple sclerosis studies	30
Neuroscience research in 2024: advances in blood biomarkers and brain omics	30
Teshamae Monteith	29
Helping to bring the crisis home	29
Blue as an orange	29
Correction to Lancet Neurol 2021; 20: 615–26	29
Global burden of meningitis and implications for strategy	29
Correction to Lancet Neurol 2023; 22: 209–17	28
Sleep matters in anti-LGI1 encephalitis	28
Friston's theory of everything	28
RAB32 mutation in Parkinson's disease	28
Correction to Lancet Neurol 2018; 17: 954–76	27
Cognitive and psychiatric features of anti-NMDA receptor encephalitis	27
Correction to Lancet Neurol 2025; 24: 880–92	27
Nitrous oxide and its neurological harms	27
Correction to Lancet Neurol 2025; 24: 969–75	26
Globally advancing neurological education in headache	25
Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis	25
Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	25
Brain amyloid on the way to dementia prevention	25
Advances in diagnosis, classification, and management of pain in Parkinson's disease	25
Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controll	25
Time to get serious about the Global Action Plan on dementia	25
Clinical characterisation of patients in the post-acute stage of anti-NMDA receptor encephalitis: a prospective cohort study and comparison with patients with schizophrenia spectrum disorders	25
A neurotransmitter with a fascinating story	24
Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021	24
Amyotrophic lateral sclerosis: a lesson in translation	24
Revisiting levodopa for advanced Parkinson's disease	24
Addressing neurological burden in the Americas	24
Abandon the NAC in α-synuclein	24
Prioritising faster, individualised rescue treatment in status epilepticus – Authors' reply	23
A disease-specific therapy in facioscapulohumeral muscular dystrophy	23
Carotid revascularisation for carotid stenosis	23
Neurology cannot be embedded in non-communicable disease agendas	22
Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority tr	22
William Harvey, neurologist?	22
Krithi Irmady	22
Prehospital screening of acute stroke with the National Institutes of Health Stroke Scale (ParaNASPP): a stepped-wedge, cluster-randomised controlled trial	22
CGRP blockade and cluster headache: another step forward	22
Differential diagnosis of suspected multiple sclerosis: global health considerations	22
Global, regional, and national burden of headache disorders, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023	22
Vittorio Marchi's staining	21
Lightning progress in child neurology in the past 20 years	21
CGRP-targeted drugs for migraine: still many uncertainties	21
Treatment of asymptomatic carotid stenosis in SPACE-2	20
With thanks to our peer reviewers in 2022	20
Cerebral amyloid angiopathy criteria: the next generation	20
Dancing with paper	20
The hidden unity of the mind	19
Fetal exposure to antiseizure medications: reassurance and concerns	19
Anticoagulation in people with atrial fibrillation after intracranial haemorrhage	19
Treatment of acute subdural haematoma – Authors' reply	19
Time to end the stigma of epilepsy	19
Innovation in the prevention of neurological diseases	19
Transforming amyotrophic lateral sclerosis into a liveable disease	18
Incremental prognostic value of acute serum biomarkers for functional outcome after traumatic brain injury (CENTER-TBI): an observational cohort study	18
Dealing with the reproducibility crisis in neuroscience from the grassroots	18
Chronic effects of inflammation on tauopathies	18
The neuropsychiatry of Parkinson's disease: advances and challenges	18
Elucidating a new path of CSF transport in the CNS	18
A biobank for Parkinson's disease and atypical parkinsonism in central Asian and Transcaucasian regions	18
Carpal tunnel syndrome: updated evidence and new questions	18
Changing views of disability	17
Natural neuroscience: rethinking brain research beyond the lab	17
Criteria for a biological definition of neuronal α-synuclein disease—a major conceptual step forward	17
Effects of spaceflight on the brain	17